July 2010
Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs). The DRx AFC Medirepair® website can be found at: http://www.drx-web.com/aa/prod_afc.htm. You can see the press release here.
May 2010
At the 2010 Society of Investigative Dermatology (SID) meeting in Atlanta, Signum presented the latest results from its IPC technology platform, delivering a talk titled: “IPC analogs: A novel topical acne therapeutic possessing antimicrobial and anti-inflammatory activity against P. acnes”. In addition it also presented two posters: poster #118 titled “Isoprenylcysteine (IPC) analogs suppress 12-O-tetradecanoylphorbol-13- acetate (TPA)-induced cytokine production in primary human keratinocytes and mouse skin in vivo” and poster #761 titled “Isoprenylcysteine (IPC) analogs: A novel topical acne therapeutic possessing antimicrobial and anti-inflammatory activity against Propionibacterium acnes”.
Feb 2010
Signum Biosciences is proud to announce the appointment of Dr. Diane Thiboutot to its scientific advisory board. Dr. Thiboutot is a research leader in the regulation of sebum production, acne and is a research collaborator for testing STM activity. See Dr. Thiboutot's Bio
Jan 2010
Signum Biosciences has been awarded a $270K grant from the Alzheimer's Drug Discovery Foundation (ADDF) to investigate, "PP2A: A novel therapeutic target for Alzheimer's Disease".
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.